Answers are grounded in this paper and cite their sources.
Multicentric study assesses treatment costs in recurrent head and neck cancer patients, highlighting regional financial disparities.
Introduction: This study investigates the financial implications of recurrent/metastatic head and neck squamous cell carcinoma in Portugal (R/M HNSCC), focusing on treatment costs during the critical first year post-diagnosis. Methods: Multicentric, retrospective, cross-sectional study including adults with R/M HNSCC ineligible for curative treatment, diagnosed between June/2017-December/2019. Sociodemographic, clinical, and healthcare resources use data were collected from medical records of nine hospitals for up to one-year post-advance disease diagnosis. The financial evaluation adopted the Portuguese public healthcare payer perspective, focusing on direct medical costs. Results: Among 377 patients, 80.6% underwent palliative treatment, while 19.4% were deemed ineligible. Most were male (92.8%), aged 50-69 years (74.5%), with primary tumors located in the oropharynx (33.2%) and oral cavity (28.7%). The median total cost/patient was €18,076 and included medication (€4,938) and non-medication (€5,974). Regional variations were noted (total cost: p=0.001; medication and non-medication: p<0.001). The South/Islands had higher overall costs, particularly in non-medication, whereas the North spent more on medication. Hospitalization was the cost-driver, representing 33% of the total cost. Conclusion: This first real-world estimate on the financial impact of R/M HNSCC in Portugal demonstrates the significant burden of managing this population, unveiling differences in costs across Portugal. Effective early HNSCC detection strategies are needed to alleviate the disease burden.
No takes yet. Share an insight, caveat, or question.
Teixeira et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: